Association of Surgical Risk With Exogenous Hormone Use in Transgender Patients

    December 2018 in “ JAMA Surgery
    Elizabeth R. Boskey, Amir H. Taghinia, Oren Ganor
    New to Spironolactone? There is a guide in the encyclopedia. Read the guide →
    Image
    Studysummary This systematic review suggests that current evidence does not support routinely discontinuing gender-affirming hormone treatments before surgery, especially testosterone and spironolactone, due to limited data on related perioperative risks.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results